Browse News
Filter News
Found 194 articles
-
Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.
6/6/2023
Pasithea Therapeutics Corp. confirmed it has received an unsolicited proposal from Lucy Scientific Discovery Inc. to acquire all outstanding shares of Pasithea common stock for per share consideration consisting of $0.60 in cash plus $0.25 worth of Lucy common stock.
-
Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference
6/1/2023
Pasithea Therapeutics Corp. announced that pre-clinical results for its lead drug candidate, PAS-004, have been accepted for a poster presentation at the 2023 Neurofibromatosis Conference taking place June 24-27, 2023, in Scottsdale, Arizona.
-
Jazz Pharmaceuticals Demonstrates Continued Leadership in Sleep Medicine with New Data Presentations at SLEEP 2023
5/31/2023
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that seven abstracts featuring new data from across its sleep medicine portfolio will be presented at SLEEP 2023, the 37th annual meeting of the Associated Professional Sleep Societies (APSS) being held June 3-7, 2023.
-
More than $5 billion poured into the longevity space in 2022, and experts say the science is now primed to make a real difference in extending human healthspan.
-
Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference
5/3/2023
Pasithea Therapeutics Corp. today announced its CEO, Tiago Reis Marques, and its VP of Business Development, Mathew Lazarus will participate in the EF Hutton Global Conference, held in New York City, May 10-11.
-
Alto Neuroscience Announces CEO Amit Etkin, M.D., Ph.D., Named as an Entrepreneur Of The Year® 2023 Bay Area Award Finalist
5/2/2023
Alto Neuroscience Announces CEO Amit Etkin, M.D., Ph.D., Named as an Entrepreneur Of The Year ® 2023 Bay Area Award Finalist.
-
Jazz Pharmaceuticals to Showcase Rapidly Expanding Oncology Pipeline and Advances in Current Product Portfolio at ASCO 2023
4/27/2023
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company, along with its partners, will present nine abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6, 2023.
-
Jazz Pharmaceuticals to Present Advancements in Neuroscience at American Academy of Neurology Annual Meeting
4/19/2023
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that eleven abstracts from across its neuroscience portfolio and pipeline, including three oral presentations, will be featured at the 75th Annual American Academy of Neurology Meeting (AAN) being held April 22-27, 2023 in Boston.
-
Alto Neuroscience to Present at the Stifel 2023 CNS Days
3/28/2023
Alto Neuroscience today announced that founder and chief executive officer, Amit Etkin, M.D., Ph.D., will present at the Stifel 2023 CNS Days on Wednesday, March 29, 2023, at 3:00 p.m. ET.
-
Jazz Pharmaceuticals to Present Data at 2023 AACR Annual Meeting Showcasing New Zepzelca® (lurbinectedin) Data and Expanded Oncology Pre-Clinical and Clinical Pipeline
3/15/2023
Jazz Pharmaceuticals plc will present five new abstracts at the American Association for Cancer Research (AACR) Annual Meeting from April 14-19, 2023.
-
MaxCyte Establishcientific Advisory Board Comprised of Globally Recognized Experts in Cell Engineering Enabling Technology
3/8/2023
MaxCyte, Inc. today announced the formation of its new Scientific Advisory Board (SAB) that will reflect the cutting edge of research in molecular design and cell engineering.
-
Capsida Biotherapeutics Appoints Susan Catalano, Ph.D. as Chief Scientific Officer
3/7/2023
Capsida Biotherapeutics Inc. ("Capsida") today announced the appointment of Susan Catalano, Ph.D., as the company's Chief Scientific Officer (CSO).
-
Alto Neuroscience CEO, Amit Etkin M.D., Ph.D., to Participate in National Academies of Sciences, Engineering and Medicine Workshop on Multimodal Biomarkers for Central Nervous System Disorders
3/7/2023
Alto Neuroscience today announced that Amit Etkin, M.D., Ph.D., founder and chief executive officer, will participate in the National Academies of Sciences, Engineering and Medicine Workshop on Multimodal Biomarkers for Central Nervous System (CNS) Disorders: Development, Integration, and Clinical Utility, taking place March 13 - 14, 2023, in Washington, D.C.
-
Alto Neuroscience to Present at the Oppenheimer 33rd Annual Healthcare Conference
3/6/2023
Alto Neuroscience today announced that founder and chief executive officer, Amit Etkin, M.D., Ph.D., will present at the Oppenheimer 33rd Annual Healthcare Conference taking place virtually.
-
Pasithea Therapeutics Chairman, Prof. Lawrence Steinman, to Deliver Keynote Address at the American Association for Advancement of Science (AAAS) Annual Meeting
3/2/2023
Pasithea Therapeutics Corp. announced that Prof. Lawrence Steinman, Pasithea’s Chairman and National Academy of Sciences Professor, will deliver the keynote address at the American Association for the Advancement of Science Annual Meeting, on March 4 from 11:30am-12:30pm ET, in Washington DC.
-
Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P. Johnson Lecture at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS)
2/23/2023
Pasithea Therapeutics Corp. today announced that Lawrence Steinman, Pasithea’s Chairman and National Academy of Sciences Professor, will deliver the Dr. Kenneth P. Johnson lecture at the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) on February 23 in San Diego, California.
-
Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award
2/16/2023
Pasithea Therapeutics Corp. announced that Prof. Lawrence Steinman, Pasithea’s Chairman and National Academy of Sciences Professor, will receive the 2023 Pioneer in Medicine Award at the 20th Annual Gathering for the Cure on February 17 as part of the 20th Annual World Congress of SBMT.
-
Erin R. McQuade, J.D., Joins Alto Neuroscience as General Counsel and Chief Administrative Officer
2/7/2023
Alto Neuroscience today announced the expansion of the company’s leadership team with the addition of Erin R. McQuade, J.D., as general counsel and chief administrative officer (CAO).
-
Alto Neuroscience Announces $60 Million in Additional Financing
1/30/2023
Alto Neuroscience Inc. today announced a $25 million equity investment by new investor, Alpha Wave Ventures.
-
Alto reported positive data from a first-of-its-kind Phase IIb trial of major depressive disorder candidate ALTO-100.